Section Arrow
ACET.NASDAQ
- Adicet Bio
(Financial Status)
Quotes are at least 15-min delayed:2025/11/04 07:40 EST
Pre Market
Last
 0.7344
+0.0044 (+0.60%)
Bid
0.74
Ask
0.76
High 0.755 
Low 0.7344 
Volume 350 
Regular Hours
Last
 0.73
-0.02 (-2.67%)
Day High 
0.77 
Prev. Close
0.75 
1-M High
1.0899 
Volume 
3.13M 
Bid
0.74
Ask
0.76
Day Low
0.7138 
Open
0.75 
1-M Low
0.7302 
Market Cap 
114.94M 
Currency USD 
P/E -- 
%Yield 11.64 
10-SMA 0.86 
20-SMA 0.91 
50-SMA 0.84 
52-W High 1.4 
52-W Low 0.4471 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.30/-1.08
Enterprise Value
129.04M
Balance Sheet
Book Value Per Share
0.87
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
PHIOPhio Pharmaceuticals Corp1.86-0.19-9.27%0.01PE
Pre Market 1.7 -0.16 -8.60%
CRBUCaribou Biosciences2.43+0.01+0.41%-- 
Pre Market 2.42 -0.01 -0.41%
IOVAIovance Biotherapeutics1.95-0.02-1.02%-- 
Pre Market 1.91 -0.04 -2.05%
RXRXRecursion Pharmaceuticals5.44-0.08-1.45%-- 
Pre Market 5.25 -0.19 -3.49%
THARTharimmune Inc.3.2+0.25+8.47%0.03PE
Pre Market 3.01 -0.19 -5.94%
Quotes are at least 15-min delayed:2025/11/04 07:40 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.